SLG-100
Dry Eye Disease (DED)
Clinical Stage (Pilot trial completed)Active
Key Facts
Indication
Dry Eye Disease (DED)
Phase
Clinical Stage (Pilot trial completed)
Status
Active
Company
About Selagine
Selagine is a private, preclinical-stage biotech developing innovative biologic and antibody-based therapies for ocular surface diseases. Its lead asset, SLG-100, is a clinical-stage biologic eye drop for Dry Eye Disease (DED) with a novel mechanism targeting cytokines and autoantibodies, while SLG-200 is a novel ophthalmic antibiotic for bacterial keratitis. The company is based in Chicago, operates from UIC's incubator, and is led by its founder, Dr. Sandeep Jain, supported by a small team of scientific and business advisors.
View full company profileTherapeutic Areas
Other Dry Eye Disease (DED) Drugs
| Drug | Company | Phase |
|---|---|---|
| Licaminlimab (OCS-02) | Oculis | Phase 2/3 |
| PRP/Excipient Formulation | ECI Therapeutics | Pre-clinical |
| ALG-1007 | Allegro Ophthalmics | Pre-clinical/Phase 1 |
| Carragelose® Eyedrops | Unither Pharmaceuticals | Commercial (Out-licensing) |
| RO-7071759 | Rohto Pharmaceutical | Phase 2 |
| Urcosimod (OK-101) | OKYO Pharma | Phase 2 |